Dr. Nizar Tannir, MD

• Hematology

• Medical Oncology

• Internal Medicine

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• American University Of Beirut Faculty Of Medicine

  Medical School, 1979

• SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance, 2023-05-26

• Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma, 2009-03-31

• Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal-cell carcinoma, 2011-10-01

• Prognostic significance of promoter CpG island methylation of obesity-related genes in non-metastatic renal cell carcinoma patients, 2017-05-23

• Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy, 2022-04-12

• Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases, 2015-07-06

• Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial, 2019-07-02

• Systemic Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma: Recent Progress and Future Directions, 2014-07-18

• A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma, 2023-07-27

• Surgical Management for Local Retroperitoneal Recurrence Of Renal Cell Carcinoma After Radical Nephrectomy, 2015-03-07

• Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy, 2017-10-24

• The Role Of Metastasectomy In Patients With Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: A Matched Controlled Analysis, 2016-03-29

• Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy, 2023-05-25

• High-Resolution Profiling of Histone H3 Lysine 36 Trimethylation in Metastatic Renal Cell Carcinoma, 2015-06-15

• Outcomes of Unselected Patients with Metastatic Clear-Cell Renal Cell Carcinoma Treated with Front-Line Pazopanib Therapy Followed by Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors (VEGFR-TKI) or Mammalian Target of Rapamycin Inhibitors (mTORi): A Single Institution Experienc, 2015-12-13

• Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer, 2013-05-06

• Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK kinase, 2013-10-29

• Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial, 2022-08-02

• Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing, 2014-07-25

• Examination of moderators of expressive writing in patients with renal cell carcinoma: the role of depression and social support, 2016-05-03

• Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions, 2021-08-27

• NSD1Inactivation andSETD2Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas, 2017-07-28

• Phase II Trial Of Neoadjuvant Axitinib In Patients With Locally Advanced Non-Metastatic Clear Cell Renal Cell Carcinoma, 2014-02-07

• A randomized phase II study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer, 2014-08-22

• Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma, 2014-10-24

• Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma, 2023-05-10

• Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214, 2019-11-13

• Genomic DNA hypomethylation and risk of renal cell carcinoma: A case-control study, 2015-12-11

• Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial, 2015-11-26

• Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer, 2023-06-26

• PARTIAL NEPHRECTOMY IN THE SETTING OF METASTATIC RENAL CELL CARCINOMA, 2014-02-08

• First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and with an Evaluable Primary Renal Tumor in the CheckMate 214 Trial, 2021-11-05

• Loss of ARID1A promotes epithelial-mesenchymal transition and sensitizes pancreatic tumors to proteotoxic stress, 2020-11-06

• Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-Line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma, 2020-09-01

• Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma, 2021-04-30

• Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma, 2020-04-30

• p53 is a master regulator of proteostasis inSMARCB1-deficient malignant rhabdoid tumors, 2019-02-11

• Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects, 2021-08-30

• AMG 386 in Combination With Sorafenib in Patients With Metastatic Clear Cell Carcinoma of the Kidney A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study, 2012-06-12

• Cabozantinib versus everolimus in advanced renal cell carcinoma, 2015-09-25

• Genomic Heterogeneity of Translocation Renal Cell Carcinoma, 2013-07-01

• A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma, 2012-06-27

• mTOR inhibitor associated noninfectious pneumonitis in patients with renal cell cancer: management, predictors, and outcomes, 2013-12-02

• Gene-environment interaction of genome-wide association study-identified susceptibility loci and meat-cooking mutagens in renal cell carcinoma etiology, 2015-11-09

• Expression of long non-coding RNAMFI2-AS1is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma, 2017-08-17

• Neuroendocrine Tumors of the Kidney: A Single Institution Experience, 2014-06-11

• Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies, 2021-11-30

• Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma, 2021-08-07

• Multilevel-analysis identify acis-expression quantitative trait locus associated with risk of renal cell carcinoma, 2015-02-25

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two National Harbor, MD, USA. 9-13 November 2016, 2016-11-16

• Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin remodeling genes, 2014-06-04

• Definitive Radiotherapy for Extracranial Oligoprogressive Metastatic Renal Cell Carcinoma as a Strategy to Defer Systemic Therapy Escalation, 2021-07-23

• Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival, 2021-09-20

• Prognosticators and Outcomes of Patients with Renal Cell Carcinoma and Adjacent Organ Invasion Treated with Radical Nephrectomy, 2015-12-18

• PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma, 2020-05-01

• Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody, 2016-06-21

• Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience, 2020-10-11

• Treatment-Free Survival after Immune Checkpoint Inhibitor Therapy vs. Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial, 2021-11-10

• Systemic therapies for the management of non-clear cell renal cell carcinoma: what works, what doesn't, and what the future holds, 2020-12-02

• Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma, 2017-02-28

• Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies, 2023-04-18

• Long-Term Survival Outcomes of Cytoreductive Nephrectomy Combined with Targeted Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis, 2021-02-09

• Autophagy mediates HIF2a degradation and suppresses renal tumorigenesis, 2014-07-07

• Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers, 2020-01-20

• Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results, 2013-03-19

• Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies Over Three Decades: Comparison Between the Cytokine (1987-2005) and the Targeted Therapy (2006-2015) Eras, 2017-04-11

• Phase II Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal Cell Carcinoma, 2017-08-10

• Immune checkpoint inhibitors inMITFfamily translocation renal cell carcinomas and genetic correlates of exceptional responders, 2018-12-27

• Targeting hypoxia-inducible factor-1a (HIF-1a) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab, 2014-11-08

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one National Harbor, MD, USA. 9-13 November 2016, 2016-11-16

• Clinically Non-Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: Natural History and Outcomes after Surgical Resection with Curative Intent, 2015-02-17

• Percentage Sarcomatoid Component as a Prognostic Indicator for Survival in Renal Cell Carcinoma with Sarcomatoid Dedifferentiation, 2015-05-23

• Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile and Transcriptional Landscape, 2017-07-14

• Development of Accurate Models for Individualized Prediction of Survival After Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma, 2012-11-23

• Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial, 2022-04-14

• Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma, 2021-09-15

• From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit, 2022-03-01

• Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Renal Cell Cancer (RCC) after Sunitinib Failure, 2011-11-10

• Potential Susceptibility Loci Identified for Renal Cell Carcinoma by Targeting Obesity-related Genes, 2017-06-16

• Phase II trial of Pemetrexed plus Gemcitabine in patients with advanced non-clear cell renal cell carcinoma, 2013-12-16

• The scientific method: pillar and pitfall of cancer research, 2014-04-08